While Global Strategy sets the initial direction, true agility is sustained through a 360-degree loop that prioritises ...
The drug acts as a prostacyclin receptor agonist, which is a fairly crowded class with several approved oral, intravenous or ...
Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...
Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...
Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...
uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot ...
Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple ...
Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results